Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A biomarker enrichment trial of anti-EGFR agents in patients with advanced colorectal cancer (aCRC) with wild-type RAS and right primary tumour location (right-PTL)

Next Previous
Trial Profile

A biomarker enrichment trial of anti-EGFR agents in patients with advanced colorectal cancer (aCRC) with wild-type RAS and right primary tumour location (right-PTL)

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 09 May 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cetuximab (Primary) ; Irinotecan (Primary) ; Oxaliplatin (Primary) ; Panitumumab (Primary)
  • Indications Adenocarcinoma; Colon cancer; Colorectal cancer
  • Focus Biomarker; Therapeutic Use
  • Acronyms ARIEL

Most Recent Events

  • 30 Apr 2024 Recruitment completion is expected on 31 Mar 2025, according to ISRCTN: Current Controlled Trials.
  • 07 Jun 2022 Trial design presented at the 58th Annual Meeting of the American Society of Clinical Oncology
  • 23 Mar 2022 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top